Treats myasthenia gravis. ANDA 212405, held by Milla Pharms. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 212405 (Pyridostigmine Bromide), held by Milla Pharms, was first approved by FDA on Apr 19, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATION Pyridostigmine bromide is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 19, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG/5ML · syrup;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters